Male genital vitiligo |
| |
| Affiliation: | 1. Dermatology department, genital disease and STD centre, Saint-Louis Hospital, 75010 Paris, France;2. Faculty of medicine, university of Paris, 750006 Paris, France;3. Department of Dermatology, Côte-d’Azur University, CHU de Nice, 06000 Nice, France;4. Inserm U1065, C3M, Côte-d’Azur University, 06204 Nice cedex 3, France;1. Department of Dermatology, CHU Lyon, Université Claude Bernard Lyon I, 69000 Lyon, France;2. Sorbonne université, Faculté de médecine, Service de Dermatologie et Allergologie, Hôpital Tenon, AP-HP, 75020 Paris, France;3. Department of Dermatology, Hôpital Saint-Louis, AP-HP Université de Paris, 75010 Paris, France;4. Pathology Department, Hôpital Saint-Louis, AP-HP, Université de Paris, Inserm U976, 75010 Paris, France;5. CEREO (National reference center for Hypereosinophilic Syndromes), 75010 Paris, France;6. Department of Internal Medicine, CHU Lille, 59000 Lille, France;7. Pathology Department, CHU Lille, 59000 Lille, France;8. Dermatology Department, CHU Nantes, 44000 Nantes, France;9. Pathology Department, CHU, 44000 Nantes, France;10. Dermatology Department, Hôpital Bichat, 75018 Paris, France;11. Pathology Department, Hôpital Bichat, 75018 Paris, France;12. Faculté de Santé de Créteil et Service de Dermatologie, APHP, Hôpital Henri-Mondor, Université Paris-Est, Créteil, France and Research Group Dynamic, EA7380, Faculté de Santé de Créteil, Ecole Nationale Vétérinaire d’Alfort, USC ANSES, Université Paris-Est Créteil, 94010 Créteil, France;13. Pathology Department, Hôpital Mondor, CHU Créteil, 94010 Créteil, France;14. Department of Internal Medicine, Hôpital Foch, 92150 Suresnes, France;15. Pathology Department, Hôpital Foch, 92150 Suresnes, France;p. Department of Dermatology, CHU Lille, Inserm U1286 INFINITE (Institute for Translational Research in Inflammation), University Lille, 59000 Lille, France;1. Dermatology, infectious diseases unit, hôpital Bonnet, 83600 Fréjus Saint-Raphaël, France;2. Fédération de médecine translationnelle, Virulence bactérienne précoce, groupe Borrelia, université de Strasbourg UR7290, France;3. Infectious diseases unit, university hospital centre, 06000 Nice, France;4. Fédération de médecine translationnelle, virulence bactérienne précoce, groupe Borrelia, université de Strasbourg UR7290, centre National de référence Borrelia, CHRU de Strasbourg, France;5. Dermatology practice, 06700 Saint-Laurent-du-Var, France;1. Department of Dermatology, CHRU de Tours, 37044 Tours Cedex 9, France;2. Department of Pathology, CHRU de Tours, 37044 Tours Cedex 9, France;3. ISP 1282 INRA University of Tours, 37000 Tours, France;4. Department of Neurology, CHRU de Tours, 37044 Tours Cedex 9, France;1. Dermatology Department, UHC Ibn Rochd, Casablanca, Morocco;2. Microbiology Department, UHC Ibn Rochd, Casablanca, Morocco;3. Infectious Diseases Department, UHC Ibn Rochd, Casablanca, Morocco;1. Department of Dermatology, Montpellier University Hospital Center, Hôpital Saint-Eloi, 80, Avenue Augustin Fliche, 34090 Montpellier, France;2. Department of Dermatology, Perpignan Hospital, 66000 Perpignan, France;3. Department of Biopathology, Montpellier University Hospital Center, Hôpital Gui de Chauliac, 34295 Montpellier, France |
| |
| Abstract: | Vitiligo is a polygenetic multifactorial disease leading to melanocytic loss in skin and sometimes in hair. Genital areas may be involved and represent a specific therapeutic challenge. Surprisingly, data on male genital vitiligo remain scarce. This review aims to collate current knowledge on male genital vitiligo and to discuss the risks and benefits of the various therapeutic approaches. Male genital vitiligo is relatively frequent and often induces marked impairment of quality of life, with a specific impact on sex life. Prompt recognition of activity remains mandatory to halt disease progression, as repigmentation remains difficult to achieve in most cases. Thanks to progress in understanding of the pathophysiology of vitiligo, new therapeutic approaches are under development. Topical ruxolitinib, a JAK pathway inhibitor, is currently the product in the most advanced stage of development, with a very encouraging repigmentation rate on the face, although specific efficacy in genital area remains to be assessed. The next generation of treatments, such as topical WNT agonists, could be of great interest in genital vitiligo as they will not require combination with UV therapy and they may be able to enhance the differentiation and proliferation of melanocyte stem cells in this difficult-to-treat area. |
| |
| Keywords: | Vitiligo Genital Scrotum Penis |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
